Randomly assigned after informed consent:
n=409

Allocation:

Assessed for eligibility, n=431

Interested potential study persons, n=522

Excluded by the study coordinator, n=91
- Too mild symptoms, n=30
- Refused to participate, n=27
- Other diagnosis, n=20
- Recent manual treatment, n=12
- Other, n=2

Excluded by the physician, n=22
- Too mild symptoms, n=9
- Other diagnosis, n=5
- Red flags, n=4
- Refused to participate, n=4

Naprapathy (Index Group)
- n=206

Evidence-based care (Control Group)
- n=203

Follow-up:
- 3 weeks (n=196; 95%)
- 7 weeks (n=194; 94%)
- 12 weeks (n=195; 95%)
- 26 weeks (n=189; 92%)
- 52 weeks (n=186; 90%)

Follow-up:
- 3 weeks (n=186; 92%)
- 7 weeks (n=184; 91%)
- 12 weeks (n=180; 89%)
- 26 weeks (n=177; 87%)
- 52 weeks (n=160; 79%)

Target population:
- n=approximately 40,000

Interested potential study persons:
- n=522

Assessed for eligibility:
- n=431

Included potential study persons:
- n=409

Reported dropouts before follow-up, n=10
- Late start n=4
- False inclusion n=3
- Depression n=2
- Dissatisfied n=1

Reported dropouts before follow-up, n=12
- Dissatisfied n=10
- Lack of time n=2

Target population
- n=approximately 40,000